2Suppliers
0Customers
2Debt Items
20Related Chains

Atea Pharmaceuticals, Inc. Suppliers

TickerNameConfidenceEvidence
MERCK-CO-INC MERCK-CO-INC 92% In December 2021, the Company entered into a license agreement with MSD International GmbH, an affiliate of Merck & Co, Inc. for the development, manufacture and commercialization of ruzasvir.
MSD-INTERNATIONAL-GMBH MSD-INTERNATIONAL-GMBH 92% In December 2021, the Company entered into a license agreement with MSD International GmbH, an affiliate of Merck & Co, Inc. for the development, manufacture and commercialization of ruzasvir.

Atea Pharmaceuticals, Inc. Customers

No clients on recordNo downstream customers found in our database for Atea Pharmaceuticals, Inc..

Atea Pharmaceuticals, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
AVIR-DEBT-7994 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.
AVIR-DEBT Debt stack $634,000 90% Market cache reports total debt of $634,000.

Atea Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Atea Pharmaceuticals, Inc..

Atea Pharmaceuticals, Inc. Ownership

HolderNameConfidenceEvidence
AVIR-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 129 tracked holders.

Atea Pharmaceuticals, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
BMY Bristol-Myers Squibb Company 100.00 2
TBPH Theravance Biopharma, Inc. 100.00 2
CRIS Curis, Inc. 100.00 2
EVAX Evaxion A/S 100.00 2
BNBX BNB Plus Corp. 100.00 2
GDTC CytoMed Therapeutics Limited 100.00 2
CAH Cardinal Health, Inc. 100.00 2
CPMV Mosaic ImmunoEngineering, Inc. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
IMMP Immutep Limited 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
VEEV Veeva Systems Inc. 100.00 2
ENLV Enlivex Ltd. 100.00 2
PSNL Personalis, Inc. 100.00 2
CABA Cabaletta Bio, Inc. 100.00 2
SDGR Schrödinger, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
ADAG Adagene Inc. 100.00 2
HOWL Werewolf Therapeutics, Inc. 100.00 2